CHEK2 and breast cancer: The predicted proportion of breast cancer cases possessing pathogenic germline missense variants in these genes is approximately 0.6%, 0.3%, 0.2%, and 1.3% for ATM, BRCA1, BRCA2, and CHEK2, respectively.